Teva's TEV-53408 Trial for Vitiligo Focuses on Safety and Efficacy
Teva is conducting a trial to assess the safety and efficacy of TEV-53408 in adults with vitiligo over an 84-week period.
Asset / Drug
Drug and asset intelligence for TEV-53408 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.